Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07659756

Global Healthcare Study on Atopic Dermatitis

The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Atopic Dermatitis (AD) Atopic Dermatitis (Eczema) Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Eczema Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

14 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed General Consent Form, or equivalent document
  • Confirmed diagnosis of Atopic Dermatitis

Exclusion criteria

  • Inability to provide informed consent.
  • Datasets with ambiguous or unclear diagnosis.

Treatment and study plan

Primary outcomes

  1. Eczema Area and Severity Index (EASI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease.

Secondary outcomes

  1. SCORing Atopic Dermatitis (SCORAD)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed measure of atopic dermatitis severity incorporating extent, intensity, and subjective symptoms; total score ranges from 0 to 103, with higher scores indicating more severe disease.

  2. Dermatology Life Quality Index (DLQI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.

  3. Patient-Oriented Eczema Measure (POEM)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported measure of atopic dermatitis symptoms and disease burden; total score ranges from 0 to 28, with higher scores indicating more severe disease.

  4. Peak Pruritus Numerical Rating Scale (PP-NRS)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported assessment of peak itch severity on a numerical rating scale from 0 (no itch) to 10 (worst imaginable itch).

  5. Physician Global Assessment (PGA)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed global measure of atopic dermatitis severity on a scale from 0 (clear) to 4 (severe).

  6. Body Surface Area (BSA)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Percentage of total body surface area affected by atopic dermatitis, ranging from 0% to 100%.

  7. Patient-reported Numerical Rating Scale (NRS) for atopic dermatitis severity

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported assessment of overall atopic dermatitis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).

Study contacts

Contact information is provided by the study sponsor or research team.

Johannes Didaskalu

CONTACT

[email protected]

Julia-Tatjana Maul, Prof. Dr. med.

CONTACT

[email protected]

+41 76 441 51 09

Sponsors and collaborators

Lead sponsor

Julia Tatjana Maul

Other

Collaborators

  • University Hospital, Zürich
  • University of Zurich

Registry information

Acronym: GHSAD

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.